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Abstract
Mutations of the HFE and TFR2 genes have been associated with iron overload. HFE and TFR2 mutations were assessed 
in blood donors, and the relationship with iron status was evaluated. Subjects (N = 542) were recruited at the Hemocentro da 
Santa Casa de São Paulo, São Paulo, Brazil. Iron status was not influenced by HFE mutations in women and was independent 
of blood donation frequency. In contrast, men carrying the HFE 282CY genotype had lower total iron-binding capacity (TIBC) 
than HFE 282CC genotype carriers. Men who donated blood for the first time and were carriers of the HFE 282CY genotype 
had higher transferrin saturation values and lower TIBC concentrations than those with the homozygous wild genotype for the 
HFE C282Y mutation. Moreover, in this group of blood donors, carriers of HFE 63DD plus 63HD genotypes had higher serum 
ferritin values than those with the homozygous wild genotype for HFE H63D mutation. Multiple linear regression analysis 
showed that HFE 282CY leads to a 17.21% increase (P = 0.018) and a 83.65% decrease (P = 0.007) in transferrin saturation 
and TIBC, respectively. In addition, serum ferritin is influenced by age (3.91%, P = 0.001) and the HFE 63HD plus DD geno-
type (55.84%, P = 0.021). In conclusion, the HFE 282Y and 65C alleles were rare, while the HFE 63D allele was frequent in 
Brazilian blood donors. The HFE C282Y and H63D mutations were associated with alterations in iron status in blood donors 
in a gender-dependent manner.
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Iron is essential for the adequate functioning of 
metabolic and structural proteins in cells. Proteins, such 
as HFE, hemojuvelin, transferrin receptor 2 (TFR2), and 
ferroportin, and a peptide called hepcidin, regulate iron 
metabolism. Mutations in the genes of these proteins or 
peptide are associated with the etiology of iron overload 
(hereditary hemochromatosis, HH), which is characterized 
by increased intestinal iron absorption and progressive 
accumulation of iron in the body (1).
The HFE protein forms a complex with β2-microglobulin 
and this complex can interact with transferrin receptor 1 
(TFR1), decreasing its affinity for transferring and con-
sequently modulating iron absorption in enterocytes (2). 
TFR2 is expressed predominantly in the liver, is implicated 
in the uptake of iron by hepatocytes through a receptor-
mediated endocytosis mechanism, and has a high degree 
of homology with TFR1 (3). 
Several mutations in the HFE gene have been associ-
ated with HH in different populations (4). The HFE G845A 
(C282Y) mutation is frequent in a healthy population from 
Northern Europe (10%) (1), but is rare or absent in African, 
Asian, South Pacific, and Aboriginal Australian populations 
(5). Higher frequencies of C282Y were found in individuals 
with HH, decreasing from Northern to Southern Europe, 
with the highest percentage occurring in Brittany (96%) (6) 
and the lowest in Italy (64%) (7) and Greece (39%) (8). 
Two other HFE mutations (C187G and A193T) are 
characterized by substitutions of histidine to aspartic 
acid at position 63 (H63D) (9) and serine to cysteine at 
position 65 (S65C), respectively (10). The HFE 63D al-
lele in the absence of the HFE 282Y allele was shown to 
be associated with a low risk for HH. However, the HFE 
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H63D mutation is inherited in heterozygosis with the HFE 
C282Y mutation, and the carrier has an elevated risk of 
developing HH compared to an individual with the HFE 
282YY genotype (7,11). 
TFR2 gene mutations are less frequent than HFE 
mutations. The TFR2 Y250X mutation, detected in a Sicil-
ian family (12), is a nonsense mutation characterized by 
impairment of TFR2 protein and, consequently, alterations 
in iron regulation. The Q690P mutation was detected in 
a Portuguese man and in two of his family members with 
the HH phenotype (13). These two mutations in TFR2 
were demonstrated in HH patients, but their frequencies 
in healthy individuals are unknown. 
A few studies have evaluated the frequency of the 
HFE C282Y mutation in Brazilian healthy individuals, 
but the effect of this mutation on iron status in Brazilian 
healthy blood donors is not known (14-16). In addition, 
the frequency of TFR2 mutations in the Brazilian healthy 
population is also not known. The objectives of this study 
were to determine the frequencies of functional mutations 
in the HFE and TFR2 genes, and to identify their relation-
ship to iron status in blood donors.
Material and Methods
Study population
This study included 542 Brazilian healthy volunteers 
randomly selected among blood donors from Hemocentro 
da Santa Casa de São Paulo, SP, Brazil, in 2005. Two Eth-
ics Committees (Santa Casa and Faculdade de Ciências 
Farmacêuticas) approved the study protocol, and written 
informed consent was obtained from all participants prior 
to entering the study.
Demographic data and the frequency of previous 
donations were obtained by a structured interview. Each 
person self-identified as White, Intermediate, Black, or 
Yellow according to the skin color categories defined by 
the Brazilian Census (17). The ethnic self-identification 
classification was compared with ancestry informative 
markers in a recent Brazilian study, which concluded that 
Brazilian individuals should be considered as a heteroge-
neous population (18,19).
Blood donors were divided into three groups accord-
ing to the frequencies of blood donations. The individu-
als who donated blood for the first time were classified 
as first-time donors. Individuals who had donated blood 
more than once in the last 12 months were classified as 
frequent donors. Last, individuals who donated blood 
any time prior to the last 12 months were classified as 
sporadic blood donors. 
Only individuals with hematocrit values higher than 39 
and 38% for men and woman, respectively, were accepted 
for blood donation and enrolled in the study (20). Blood 
donors with altered liver function and/or with hepatitis C 
were excluded from the study.
Blood sampling and laboratory determinations
Peripheral venous blood was drawn using BD Vacu-
tainer System® containing K3EDTA (Becton Dickinson, 
USA) for blood cell counts and genetic analysis. An 
additional blood sample was collected into a BD Vacu-
tainer System® without anticoagulant for measurements 
of serum iron (SI), serum ferritin (SF), total iron-binding 
capacity (TIBC), alanine (ALT) and aspartate (AST) 
aminotransferase activities, and hepatitis C and B im-
munological markers. 
SI, TIBC, ALT, and AST were measured by colorimetric 
and enzymatic assays using the automated system Advia 
1650® (Bayer Diagnostics, USA). Transferrin saturation 
(TS) was estimated as the ratio between SI and TIBC and 
reported as percentage. SF was determined by an immune 
assay using the Axsym System® (Abbott Laboratories, 
USA). Hepatitis C and B were detected by immune as-
says using the Murex anti-HCV® kit (Murex Biotech S.A., 
South Africa) and the Hepanostika anti-HBc Uni-Form® 
and Hepanostika HbsAg Uni-FormII® kits (BioMérieux, 
The Netherlands), respectively.
Genetic analysis 
Genomic DNA was isolated from whole blood by a 
salting-out method previously reported (21). HFE C282Y 
and TFR2 Y250X mutations were detected by the poly-
merase chain reaction and restriction fragment length poly-
morphism analysis (PCR-RFLP) as previously described 
(22,23). The primer sequences (Invitrogen, Brazil) for 
genotyping the HFE (H63D and S65C) and TFR2 Q690P 
mutations were modified in the present study using the 
Primer Premier version 5.0 software (Sigma Chemical 
Co., USA) based on previously published sequences 
(10,13). For amplification of the HFE H63D and S65C 
mutations, we used the following primer sequences: for-
ward 5’-TGTTGCTCTGTCTCCAGGTTCA-3’ and reverse 
5’-CACAACCACAGCAAGGGTATGT-3’, using 34 cycles 
and a hybridization temperature of 63°C. The TFR2 Q690P 
mutation was amplified using the following primer sequences: 
forward 5’-CTCCAGCACTCTGTCCTCGTCTA-3’ and 
reverse 5’-GCGATCAAAGTGATGAAATGGA-3’, using 30 
cycles and a hybridization temperature of 60°C. The PCR 
assays were carried out using the Eppendorf Mastercycler 
(Eppendorf, Germany).
PCR products were digested with the RsaI, MboI, 
HinfI, and BfaI endonucleases (New England Biolabs Inc., 
USA) to detect the HFE C282Y, HFE H63D, HFE S65C, 
and TFR2 Y250X mutations, respectively. The restriction 
assay for TFR2 Q690P genotyping was carried out by 
double digestion with BfaI and HpaII (New England Biolabs 
Inc.) to differentiate fragments of similar size after HpaII 
digestion. Restriction fragments were analyzed by elec-
trophoresis on 2% agarose gel (HFE C282Y, HFE H63D, 
HFE S65C, and TFR2 Y250X) and 8% polyacrylamide 
gel (TFR2 Q690P).
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Statistical analysis
Hardy-Weinberg equilibrium was determined for all 
genotypes using the chi-square test. The distributions of 
concentrations of SI, TIBC, TS, and SF were all skewed. Log-
transformation removed this skew and the variables became 
normally distributed in order to be used in the parametric 
tests. Age was skewed because of the difference between 
groups and was analyzed by the Mann-Whitney test.
The chi-square test or the Fisher exact test was also 
used to compare the frequencies of donations, genotypes 
for the HFE C282Y, H63D and S65C mutations, and ethnic 
groups according to blood donor gender. 
One-way analysis of variance (ANOVA), adjusted by 
age and number of blood donations, was used 
to compare the mean concentrations of SI, TIBC, 
TS, and SF from the female and male blood do-
nor groups, formed according to genotypes for 
three HFE mutations. The same comparisons 
were performed in groups formed according to 
the number of blood donations. When ANOVA 
was significant, the Tukey-Kramer post-test was 
performed to determine significant differences 
among groups. 
To assess the simultaneous relationship be-
tween the various predictors of SF, TS, and TIBC 
in the male donors at their first blood donation 
(as dependent variables), three models of mul-
tiple linear regression analysis were used. The 
independent variables were: age, White versus 
non-White individuals (the non-White group was 
the reference, and 2 Yellow individuals were ex-
cluded from this model), CY versus CC genotype 
for HFE C282Y mutation (the CC genotype was 
the reference), HD + DD versus HH genotype for 
the HFE H63D mutation (the HH genotype was 
the reference) and SC versus SS genotype for 
the HFE S65C mutation (the SS genotype was 
the reference). 
All statistical analyses were carried out using 
statistical analysis software (SAS - Statistical 
Analysis System for Windows, version 8.02, SAS 
Institute Inc., USA), with the level of significance 
set at P < 0.05.
Results
General data of the sample population
Of the 542 eligible subjects, 371 (68.5%) were 
male donors. The distribution of age, color groups, 
blood donation frequency groups, frequencies of 
HFE genotypes and HFE combined genotypes 
are presented in Table 1. 
The frequencies of blood donation differed 
between genders. The percentage of women 
(35.7%) was significantly higher than the percent-
age of men (20.8%, P < 0.001) in the first-time donor group, 
while there was a higher percentage of men (45.0%) than 
women (32.7%, P < 0.001) in the frequent donor group 
(Table 1). 
Frequencies of the HFE and TFR2 mutations
The frequencies of the HFE 282Y, HFE 63D and HFE 
65C alleles were 2.1, 13.6, and 0.6%, respectively. No 
difference was found in the allele frequencies in male and 
female blood donors according to the skin color (P > 0.05). 
The genotype distributions for HFE mutations were in Hardy-
Weinberg equilibrium (Table 1). The TFR2 250X and TFR2 
690P alleles were not detected in a subpopulation of donors 
Table 1. Demographic and genetic characteristics of the blood donors who 
participated in the present study.
Women, N (%) Men, N (%)
Gender 171 371
Age (years)*** 31.3 (29.8-32.9) 32.6 (31.6-33.7)
Skin color*
White 91 (53.4) 201 (54.2)
Intermediate 56 (32.9) 110 (29.7)
Black 21 (12.4) 58 (15.6)
Yellow 2 (1.3) 2 (0.5)
Frequency of blood donations**
First time 61 (35.7) 77 (20.8)
Sporadic 54 (31.6) 127 (34.2)
Frequent 56 (32.7) 167 (45.0)
HFE C282Y genotype**
CC 164 (95.9) 355 (95.7)
CY 7 (4.1) 16 (4.3)
HFE H63D genotype*
HH 130 (76.0) 275 (74.1)
HD 38 (22.2) 89 (24.0)
DD 3 (1.8) 7 (1.9)
HFE S65C genotype*
SS 171 (100.0) 365 (98.4)
SC 0 6 (1.6)
HFE combined genotype C282Y/H63D/S65C*
CC/HH/SS 124 (72.5) 256 (69.0)
CC/HD/SS 37 (21.6) 86 (23.2)
CY/HH/SS 6 (3.5) 13 (3.5)
CC/DD/SS 3 (1.8) 7 (1.9)
CC/HH/SC 0 6 (1.6)
CY/HD/SS 1 (0.6) 3 (0.8)
N = number of subjects. Age = reported as the geometric mean; 95%CI in 
parentheses. The genotype distribution for HFE gene mutation of female and 
male blood donors was in Hardy-Weinberg equilibrium. *Fisher exact, **chi-
square, and ***Mann-Whitney tests were performed. There was a significant 
difference between frequencies of blood donations according to gender (P < 
0.001). Other comparisons were non-significant (P > 0.05).
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from this study (212 donors for the TFR2 Y250X mutation 
and 516 for the TFR2 Q690P mutation).
Relationship between HFE mutations and iron status
SI, TIBC, TS, and SF were not associated with the HFE 
C282Y or H63D genotype in women (P > 0.05; Table 2). 
The 65C allele was not detected in women. 
Interestingly, TIBC was lower in men carrying the 
HFE 282CY genotype when compared with the 282CC 
genotype carriers (P = 0.003; Table 2). In addition, 
higher SI and TS values were found in men carrying at 
least one HFE 63D allele (HD plus DD genotypes) than 
in HH genotype carriers (P < 0.05). No relationship was 
found between HFE S65C genotype and iron status in 
men (Table 2). 
Relationship between HFE mutations and iron status 
according to blood donation frequency
The lack of association between the HFE C282Y and 
H63D genotypes and the SI, TIBC, TS, and SF data for 
Table 2. Iron status according to HFE C282Y, H63D, and S65C mutations in blood donors.
Serum iron (µg/dL) TIBC (µg/dL) Transferrin saturation (%) Serum ferritin (µg/L)
Women
HFE C282Y
CC 75.1 (69.6-81.0) 339.4 (328.9-350.3) 21.9 (22.0-23.8) 28.1 (24.0-32.9) 
N = 164 N =164 N = 164 N = 155
CY 94.3 (69.0-128.9) 333.8 (264.6-421.1) 28.2 (19.3-41.2) 24.8 (11.3-54.5) 
N = 7 N = 7 N = 7 N = 7
HFE H63D
HH 75.5 (69.4-82.1) 339.9 (327.8-352.3) 22.0 (20.0-24.2) 27.3 (22.9-32.4) 
N = 130 N = 130 N = 130 N = 125
HD + DD 76.9 (65.9-89.6) 336.9 (216.0-359.0) 22.7 (19.4-26.5) 30.5 (21.8-42.6) 
N = 41 N = 41 N = 41 N = 37
Men
HFE C282Y
CC 87.8 (84.4-91.3) 311.3 (305.3-317.3) 28.0 (26.8-29.2) 90.4 (82.4-99.1)
N = 355 N = 355 N = 355 N = 328
CY 86.2 (70.0-106.1) 262.6 (207.0-333.3) 31.1 (24.1-40.3) 133.0 (92.3-191.6)
N = 16 N = 16 N = 16 N = 16
P 0.003
HFE H63D
HH 88.3 (81.4-89.3) 307.8 (300.1-315.7) 27.4 (26.0-28.8) 88.7 (80.1-98.3)
N = 275 N = 275 N = 275 N = 256
HD + DD 95.2 (89.2-101.6) 312.4 (301.2-324.1) 30.3 (28.3-32.4) 102.3 (84.9-123.4)
N = 96 N = 96 N = 96 N = 88
P 0.016 0.048
HFE S65C
SS 87.6 (84.2-91.1) 309.5 (303.0-316.1) 28.0 (26.8-29.2) 91.7 (83.7-100.4)
N = 365 N = 365 N = 365 N = 338
SC 97.3 (73.3-129.2) 281.6 (241.0-328.9) 34.3 (25.0-46.9) 111.7 (61.2-203.9)
N = 6 N = 6 N = 6 N = 6
Data are reported as geometric mean with 95%CI in parentheses. N = number of subjects; TIBC = total iron- 
binding capacity. The statistical analyses were performed on the log-transformed variables. ANOVA was ad-
justed by the number of donations in the last 12 months and blood donor age. The HFE 65C allele was not 
detected in female blood donors.
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women was independent of first blood donation (P > 0.05; 
Table 3). 
First-time male blood donors carrying the HFE 282CY 
genotype had lower TIBC (P < 0.001) and higher TS (P = 
0.020) values than the 282CC carriers (Table 3). In this 
group, the HFE 63D allele (DD plus 63HD genotypes) was 
associated with increased SF concentrations (P = 0.015). 
On the other hand, the HFE S65C mutation did not affect 
the iron variables in this sample (Table 3). 
No relationship was found between HFE C282Y, H63D 
and S65C mutations and iron variables in sporadic or 
frequent blood donors, independent of gender (data not 
shown, P > 0.05).
Predictors of serum ferritin, transferrin saturation 
and TIBC
Multiple linear regression analysis was used to evaluate 
the association between HFE genotype and other variables 
on SF (model 1), TS (model 2) and TIBC (model 3) values 
in first-time male blood donors (Table 4). Age (3.91%, P 
= 0.001) and HFE 63HD plus 63DD genotypes (55.84%, 
P = 0.021) were predictors of increased SF concentra-
Table 3. Iron status according to HFE C282Y, H63D, and S65C mutations in first-time blood donors.
Serum iron (µg/dL) TIBC (µg/dL) Transferrin saturation (%) Serum ferritin (µg/L)
Women
HFE C282Y
CC 79.2 (70.0-89.7) 336.3 (318.1-355.5) 23.2 (20.2-26.7) 33.7 (26.6-42.8)
N = 58 N = 58 N = 58 N = 56
CY 95.2 (49.1-184.5) 368.6 (189.5-716.9) 25.7 (15.8-41.8) 18.8 (2.6-135.4)
N = 3 N = 3 N = 3 N = 3
HFE H63D
HH 81.6 (71.6-93.1) 339.0 (317.5-362.0) 23.7 (20.2-27.8) 31.8 (23.3-43.5)
N = 43 N = 43 N = 43 N = 42
HD + DD 76.1 (57.9-99.9) 334.8 (300.4-373.2) 22.3 (17.0-29.2) 35.1 (26.4-46.7)
N = 18 N = 18 N = 18 N = 17
Men
HFE C282Y
CC 89.7 (81.0-99.2) 301.1 (288.3-314.4) 29.7 (26.6-33.1) 122.2 (105.6-141.5)
N = 72 N = 72 N = 72 N = 65
CY 109.4 (62.7-190.9) 189.6 (82.9-434.0) 48.8 (36.2-65.8) 138.9 (58.8-328.4)
N = 5 N = 5 N = 5 N = 5
P <0.001 0.020
HFE H63D
HH 90.9 (80.4-102.8) 289.2 (268.0-312.0) 30.9 (27.1-35.2) 112.1 (96.1-130.8)
N = 57 N = 57 N = 57 N = 53
HD + DD 90.6 (77.0-106.4) 301.0 (277.3-326.3) 30.0 (25.0-36.1) 166.0 (120.8-228.0)
N = 20 N = 20 N = 20 N = 17
P 0.015
HFE S65C
SS 90.4 (81.8-100.0) 291.7 (274.5-310.1) 30.6 (27.4-34.1) 125.2 (108.4-144.6)
N = 75 N = 75 N = 75 N = 68
SC 106.7 (5.9-1923.8) 306.5 (265.1-354.3) 34.5 (1.5-777.0) 74.3 (22.3-247.0)
N = 2 N = 2 N = 2 N = 2
Data are reported as geometric mean with 95%CI in parentheses. N = number of subjects; TIBC = total iron-binding 
capacity. The statistical analyses were performed on the log-transformed variables. ANOVA was adjusted by blood donor 
age. The HFE 65C allele was not detected in female blood donors.
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tions, while the HFE 282CY genotype was associated 
with increased TS (17.21%, P = 0.018) and reduced TIBC 
(-83.65%, P = 0.007) values. 
Discussion
 
In the present study, the frequency of the HFE 282Y 
allele (2.1%, P > 0.05) was similar to that reported in 
studies conducted in healthy Brazilian individuals (1.1 to 
1.4%) (14-16) and in blood donors from Colombia (1.8%) 
(24). However, the frequency of this allele was lower (P < 
0.05) than those found in blood donors from Northern Italy 
(4.7%) (25) and Northern Europe (5.1 to 8.2%) (5,26,27). 
In addition, it is known that the HFE C282Y mutation is rare 
in non-Caucasians (5,28). The low frequency of the HFE 
282Y allele found in the present study could be explained 
by the high heterogeneity of the ethnic composition of the 
Brazilian population, which is the result of five centuries of 
interethnic crosses of peoples from three continents: the 
European colonizers mainly represented by the Portuguese, 
the African slaves, and the autochthonous Amerindians 
(18). We did not find differences in the frequency of the 
Table 4. Influence of HFE C282Y, H63D, and S65C mutations and other variables on iron status in first-time 
male blood donors by multiple linear regression analysis.
Dependent variables Independent variables Parameter Standard error P 
Serum ferritin Intercept -3.13 35.62
Model 1 (N = 71) Age 3.91 1.17 0.001
White men 40.31 21.35
HFE 282CY genotype 35.13 39.80
HFE 63HD plus 63DD genotypes 55.84 23.57 0.021
HFE 65SC genotype -48.67 62.63
Transferrin saturation Intercept 28.96 6.29 <0.001
Model 2 (N = 77) Age 0.08 0.20
White men 3.21 3.71
HFE 282CY genotype 17.21 7.09 0.018
HFE 63HD plus 63DD genotypes -1.47 3.94
HFE 65SC genotype 1.60 11.14
TIBC Intercept 317.08 26.74 <0.001
Model 3 (N = 77) Age -0.48 0.85
White men 1.98 15.76
HFE 282CY genotype -83.65 30.12 0.007
HFE 63HD plus 63DD genotypes 3.69 16.74
HFE 65SC genotype -2.03 47.35
N = number of subjects; TIBC = total iron-binding capacity. The non-White group consisted of Intermediate 
and Black men, excluding Yellow individuals (N = 2). Three models of multiple linear regression analysis were 
done. Model 1 = the independent variables were: age; White versus non-White individuals (non-White group 
was the reference); HFE 282CY versus CC genotype (CC genotype was the reference); HFE 63HD plus DD 
versus HH genotype (HH genotype was the reference); HFE 65SC versus SS genotype (SS genotype was 
the reference). Models 2 and 3 = the independent variables were the same as in Model 1.
282Y allele between White and Intermediate plus Black 
individuals (P > 0.05). However, the ethnic classification 
was based on self-identified skin color categorization, which 
could be considered a limitation of this study. 
The frequency of the HFE 63D allele in the present study 
(13.6%, P > 0.05) was similar to that found in studies with 
blood donors from several regions of Italy (14.4-14.9%) 
(25,29), in White individuals from the United States (15.0%) 
(30), and in two studies of healthy Brazilian blood donors 
(10.8 and 10.9%, P > 0.05) (14,15).
The HFE 65C allele frequency (0.6%, P > 0.05) in this 
sample was similar to that found in another Brazilian study 
(1.0%) (15) and in blood donors from Northern Italy (0.74%) 
(25) and from the Faroe Islands (1.0%) (27).
To our knowledge, this is the first investigation of TFR2 
mutations in a Brazilian population. These mutations were 
evaluated in Brazilian individuals because it is estimated 
that approximately 500,000 Portuguese arrived in the 
country between 1500 and 1808; Brazil also received ap-
proximately 4 million immigrants from other parts of the 
world (Italy, Spain, and German) (31). However, the TFR2 
690P and TFR2 250X alleles (initially found in Portuguese 
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